Open vs partial nephrectomy, and open vs robotic prostatectomy - two large randomised trials that did not change surgical practice! Just as important to examine these in GU Cast Journal Club as to examine pivotal trials that did change practice. Today we discuss the EORTC Today we discuss the EORTC 30904 RCT looking at kidney cancer surgery (Eur Urol 2011), and the Brisbane randomised trial of open vs robotic prostatectomy conducted (Lancet 2016).

Welcome back Rana McKay! Renu was on a flight to Europe this week so Rana jumped into her seat in the GU Cast studio this week to have a chat about the intriguing ARASEC trial which she presented at the AUA Annual Meeting recently. Plus her thoughts on the ARACOG data presented at ASCO last month. And then a great chat with our other studio guest, Professor Renea Taylor, translational scientist at Peter Mac and Monash University, about the very interesting Early Onset Prostate Cancer project, an international collaboration which herself and Rana are both very involved with, looking at the reasons behind why younger men are turning up with aggressive prostate cancer.

Tips and tricks for nerve-sparing surgery, learned over 25 years of performing robotic radical prostatectomy. Today we are joined by Dr Ash Tewari, Chief of Urology at Mt Sinai (New York), to talk about his favourite topic - nerve-sparing surgery - and a little about his second favourite topic - cricket! Ash has been one of the world's foremost experts in robotic prostatectomy having been there at the very start when Mani Menon was developing the technique, and has studied the anatomy of nerve-sparing prostatectomy in fine detail. Today we chat through his thoughts on the optimal approach to nerve-sparing prostatectomy to deliver the best outcomes for our patients. Some surgical footage included on the YouTube version.

Hot topics in a hot city!! Declan and Renu escaped from deep Winter in Melbourne and landed into the hottest day on record in Berlin!! We are here to help with the Astellas Global Prostate Cancer Masterclass, a wonderful two day meeting focussing on advanced prostate cancer. Delegates from all over the world and a top class local and International faculty. We catch up with great friends of GU Cast Stephen Freedland (Cedars-Sinai Medical Centre, Los Angeles) and Bertrand Tombal (UC Louvain, Brussels), to pick their brains on hot topics in this hot city.

All you need to know about enfortumab vedotin (EV) & pembro in bladder cancer in 25 minutes! We are joined in studio by bladder cancer gurus Shilpa Gupta (Cleveland Clinic, USA) and Andrew Weickhardt (Austin Health, AUS) to get an update on the role of EV-pembro in both muscle-invasive localised bladder cancer, and metastatic bladder cancer

Yep it's been a buzz word in testis cancer for a while now, but with the read-out of the CLIMATE and SWOG 1823 trials in the past six months, we thought we better get ourselves updated on this exciting biomarker. We are joined in studio by testis cancer gurus Ben Tran (Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne), and online by Aditya Bagrodia (Urologist, UCSD, San Diego), to give us a bluffers guide to miR-371.

Welcome to Episode 8 of our monthly GU Cast Journal Club! Today we focus on two very important papers in localised prostate cancer and metastatic bladder cancer. The landmark 15 year update of the PROTECT trial, published in NEJM in 2023, and the breakthrough EV-301 trial which heralded enfortumab vedotin in progressive metastatic bladder cancer, published in NEJM in 2021.

Renu had been to an excellent Bayer Apex meeting in Europe in the past, so was very happy to hear Apex was coming to us for its first Asia-Pacific outing! A wonderful prostate cancer Faculty headlined by Neal Shore, Dan George, Derya Tilki, Fred Saad, Amit Bahl, Tamim Niazi to name but a few, plus almost 200 delegates from across the APAC region

Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery.

Two interesting papers caught the eye of our GU Cast China team this week; the first is the ARASEC trial which Dr Rana McKay read out in the Practice-Changing Plenary at the AUA Annual Meeting in Washington. This is an interesting comparison of ADT + darolutamide for mHSPC in a prospective US cohort, compared with an historical ADT-only control arm from CHAARTED. Interesting study design and interesting results. The second is the ADT Lead-In study led bu GU Cast China Editor, Dr Yao Zhu, which demonstrates how the timing of docetaxel chemotherapy in mHSPC can significnatly affect the likelihood of severe neutropenia. Your usual ho

Now this is an interesting one, a new PSMA tracer which appears to greatly outperform 68Ga-PSMA-11 for biochemical recurrence. We discuss 64Cu-SAR-bisPSMA with Professor Louise Emmett (Nuclear Medicine Physician, Sydney), and Dr Matt Roberts (Urologist, Brisbane), which they compared head to head with trusty old 68Ga-PSMA-11 in the Co-PSMA trial, just published in European Urology.

One of our most popular podcasts every year is when we chat with EAU Guideline gurus Derya Tilki and Gianluca Giannarini about the latest updates to the EAU Prostate Cancer Guideline. It is a 250 word document which is updated in March every year and changes are eagerly awaited around the world. We catch up with Derya (Vice Chair of the Prostate Cancer Guidleine Committee) in person in Melbourne, and with Gianluca (Vice-Chair of the EAU Guideline Office) online, about the latest updates. We also chat with Gianluca about the work of the Guideline Dissemination Committee which he has Chaired for a number of years.

Democracy in action! This month's GU Cast Journal Club papers were chosen by an audience vote at our GU Cast Live Event at EAU in London. Therefore today we focus on first, the landmark proPSMA paper which established the superior accuracy of PSMA PET/CT for staging unfavourable intermediate and high-risk prostate cancer (Lancet 2020). Then for something completely different, we dig out a paper called "Penile fractures - the merry price of Christmas", published in BJUI 2020. Thanks very much to our live audience for this one!

The trial they said would never be done! Huge congrats to the Alliance for Clinical Trials in Oncology who have recently opened the ASPIRE trial, a phase III randomised trial of ADT + apalutamide (doublet), vs ADT + apalutamide + docetaxel chemotherapy (triplet) for men with mHSPC. 1200 men will be recruited from more than 300 sites across the US with many sites already open and recruiting. This is the key trial which will answer the question of whether there is an overall survival benefit of adding chemo to the ADT/ARPI doublet which we all agree is standard of care.

Our biggest live show to date! Taking to the huge eUro 2 auditorium at this month's EAU Annual Meeting in London, Declan Murphy and Renu Eapen bring you a fast-paced, high-energy session packed with favourite guests, controversial topics, behind-the-scenes stories, and lots of great giveaways, all boosted by having hundreds of our loyal supporters there in the audience with us.

Big day at the EAU Annual Meeting n London today, as our colleague Dr James Buteau (Nuclear Medicine Physician, Peter MacCallum Cancer Centre, Melbourne), reads out the PRIMARY 2 RCT at the Practice-Changing Plenary in London. Plus a simultaneous publication in Lancet Oncology. Big news for the early detection of prostate cancer, especially for patients with normal or equivocal MRI scans. 

We bring you highlights from a fantastic two day meeting at the ORSI Academy in Belgium, focussing on the hot topic of intra-operative margin assessment (IOMA), especially during prostate cancer surgery. Following on from the publication of the Neurosafe Proof RCT last year, there has been a surge in interest in new technologies to facilitate IOMS, in particular the Histolog confocal laser microscope (Samantree Medical).

Yes that's right, our great APCCC giveaway is back! We are sending three lucky winners to Lugano to attend the world's best prostate cancer meeting - the Advanced Prostate Cancer Consensus Conference. Just send us a 60 second video to enter. Closing date Fri 13th June 9pm GMT. Winners will be announced at the GU Cast Live Event at the EAU in London on Sun 15th March 2026.

Welcome to Episode 6 of our monthly GU Cast Journal Club! Two important papers in upper tract urothelial cancer (the POUT trial of adjuvant chemo post nephro-ureterectomy), and metastatic testicular cancer (the SEMS trial of surgery for early metastatic seminoma). We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. No prostate cancer today, and go easy on Declan he is struggling with man flu!

It is the eve of the USANZ ASM here in Melbourne (which Renu is Convening!), and some of the 27 International guests are already into town. So we grabbed Anders Bjartell (Lund University/University Hospital Malmo, SWE), for a sit down chat in studio. Anders has been a huge name in prostate cancer research in Europe for the past couple of decades, including as a senior investigator on TITAN. so we decided to pick his brain on three topical areas in prostate cancer.